314 related articles for article (PubMed ID: 28732326)
1. Therapeutic applications of histone deacetylase inhibitors in sarcoma.
Tang F; Choy E; Tu C; Hornicek F; Duan Z
Cancer Treat Rev; 2017 Sep; 59():33-45. PubMed ID: 28732326
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
Mastoraki A; Schizas D; Vlachou P; Melissaridou NM; Charalampakis N; Fioretzaki R; Kole C; Savvidou O; Vassiliu P; Pikoulis E
Mol Diagn Ther; 2020 Oct; 24(5):557-569. PubMed ID: 32696211
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.
Chu QS; Nielsen TO; Alcindor T; Gupta A; Endo M; Goytain A; Xu H; Verma S; Tozer R; Knowling M; Bramwell VB; Powers J; Seymour LK; Eisenhauer EA
Ann Oncol; 2015 May; 26(5):973-981. PubMed ID: 25632070
[TBL] [Abstract][Full Text] [Related]
7. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Sharma NL; Groselj B; Hamdy FC; Kiltie AE
BJU Int; 2013 Apr; 111(4):537-42. PubMed ID: 23551441
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
Sonnemann J; Dreyer L; Hartwig M; Palani CD; Hong le TT; Klier U; Bröker B; Völker U; Beck JF
J Cancer Res Clin Oncol; 2007 Nov; 133(11):847-58. PubMed ID: 17486365
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Sonnemann J; Kumar KS; Heesch S; Müller C; Hartwig C; Maass M; Bader P; Beck JF
Int J Oncol; 2006 Mar; 28(3):755-66. PubMed ID: 16465382
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors promote osteoblast maturation.
Schroeder TM; Westendorf JJ
J Bone Miner Res; 2005 Dec; 20(12):2254-63. PubMed ID: 16294278
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors: a new perspective for the treatment of leukemia.
Abujamra AL; Dos Santos MP; Roesler R; Schwartsmann G; Brunetto AL
Leuk Res; 2010 Jun; 34(6):687-95. PubMed ID: 19762081
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
17. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 clinical trials for sarcomas: the cutting edge.
Subbiah V; Kurzrock R
Curr Opin Oncol; 2011 Jul; 23(4):352-60. PubMed ID: 21519259
[TBL] [Abstract][Full Text] [Related]
19. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
Riedel RF
Semin Oncol; 2011 Oct; 38 Suppl 3():S30-42. PubMed ID: 22055970
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.
Wang M; Fang X; Wang X
Leuk Lymphoma; 2020 Apr; 61(4):763-775. PubMed ID: 31766900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
